Fate Therapeutics Stock Price, News & Analysis (NASDAQ:FATE)

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics Inc (NASDAQ:FATE) announced its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.04. The biopharmaceutical company had revenue of $2.80 million for the quarter, compared to analysts' expectations of $1.09 million. Fate Therapeutics had a negative net margin of 934.70% and a negative return on equity of 50.05%. The firm's revenue was up 180.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.37) EPS. View Fate Therapeutics' Earnings History.

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Fate Therapeutics.

16 analysts have issued 1-year target prices for Fate Therapeutics' shares. Their forecasts range from $17.00 to $32.00. On average, they anticipate Fate Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

Media headlines about FATE stock have been trending very negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fate Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT) and Sangamo Therapeutics (SGMO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Amicus Therapeutics (FOLD), Neurocrine Biosciences (NBIX), Portola Pharmaceuticals (PTLA) and Rigel Pharmaceuticals (RIGL).

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $14.75.

Fate Therapeutics has a market capitalization of $964.44 million and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]